Literature DB >> 2186871

Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract.

I Gonda1.   

Abstract

Inhaled therapeutic and diagnostic aerosols are examples of targeted delivery systems: they achieve high concentration in the respiratory tract (the usual target organ with these systems) while appearing in low concentrations in other parts of the human body. Development and use of inhalation aerosols requires an appreciation of the properties of these dynamic systems and the ways in which they interact with the anatomically and pathophysiologically complex human respiratory tract. The amounts of aerosol particles, or droplets, initially deposited at various sites in the respiratory tract will determine the intensity of local effects as well as the rate of clearance of these materials from the respiratory lumen. This activity can be modulated by suitable formulation intervention, such as presentation of the active agent in a slow releasing form carrier. Extension of duration of action of inhaled drugs by such means could be possible. As more discriminating methods for location of receptors and for the following of the fate of inhaled drugs and their carriers are becoming available, the ultimate potential for improvement of selective toxicity of agents used in pulmonary therapy by direct delivery into the respiratory tract can be critically evaluated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186871

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  6 in total

1.  Product lifecycle approach to cascade impaction measurements.

Authors:  Terrence P Tougas; Dave Christopher; Jolyon Mitchell; Svetlana Lyapustina; Michiel Van Oort; Richard Bauer; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

Review 2.  Treatment of childhood asthma. Options and rationale for inhaled therapy.

Authors:  C V Powell; M L Everard
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

3.  Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).

Authors:  Jahidur Rashid; Brijeshkumar Patel; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2017-02-07       Impact factor: 9.776

4.  Increase in the specific surface area of budesonide during storage postmicronization.

Authors:  Vidya Joshi; Sarvajna Dwivedi; Gary H Ward
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

5.  Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide.

Authors:  Mohammed-Nurul Momin; Atoosa Hedayati; Ali Nokhodchi
Journal:  Bioimpacts       Date:  2011-08-05

6.  Sustained bronchodilation with isoproterenol poly(glycolide-co-lactide) microspheres.

Authors:  Y L Lai; R C Mehta; A A Thacker; S D Yoo; P J McNamara; P P DeLuca
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.